Acumen cruises into the fast lane with novel Alzheimer’s treatment

The company’s distinct amyloid-beta target, which just won a fast track designation, could give it an edge over the competition.

By Meagan Parrish • Nov. 3, 2022

Pharma execs on creating a better workplace culture

Top women execs speak to the leadership skills they are embracing as the industry adjusts to a new normal.

By Taren Grom • Oct. 28, 2022

Explore the Trendline➔

Oncology R&D

Cancer research remains a prime focus for the industry and often leads to pharma’s most impactful breakthroughs.   

By PharmaVoice staff

The first company to use Nobel-winning click chemistry in humans is on a mission to transform oncology

Shasqi founder and CEO José Mejía Oneto on how the company’s approach could provide a more effective alternative to ADCs and other emerging cancer therapies.

By Karissa Waddick • Oct. 27, 2022

Riches, rags, riches: Is Biogen the Cinderella of biotechs?

Biogen and Eisai's new Alzheimer's drug is wowing investigators, and it might help the companies get past previous failures.

By Michael Gibney • Oct. 27, 2022

A longtime believer in mRNA, Strand Therapeutics’ co-founder is now pushing the tech to the next level

The company’s co-founder and head of R&D on how it’s using synthetic mRNA to create “smarter” therapies that could provide cures for cancer and more.

By Alexandra Pecci • Oct. 25, 2022

Beyond cancer: Scientists push CAR-T cell therapies into new frontiers

Why a ‘very exciting’ trial of the therapy in lupus patients could swing the door open to new studies in autoimmune diseases.

By Kelly Bilodeau • Oct. 24, 2022

What’s keeping pharma leaders up at night

C-suite execs in the life sciences share their late-night thoughts including innovation, patient access and market factors.

By Taren Grom • Oct. 21, 2022

How a company aimed at bringing the woolly mammoth back to life spun off a startup that could speed drug development

Colossal Biosciences announced the creation of Form Bio — and its “operating system for science” — in September.

By Alexandra Pecci • Oct. 20, 2022

5 impactful drug trial failures from the last year

Major recent trial flops and what they mean for companies, patients and the industry.

By Meagan Parrish • Oct. 19, 2022

A new class of drugs with ‘huge’ potential in the fight against challenging breast cancers

Drug developers have been making headway in treating the most difficult and deadly forms of breast cancer.

By Kelly Bilodeau • Oct. 18, 2022

Think your company could be on HHS’ drug price negotiation list? Here’s how to navigate next steps

Know what to expect from the CMS over the next few months as it implements the drug reforms laid out in the Inflation Reduction Act.

By Karissa Waddick • Oct. 18, 2022

The Novartis U.S. Foundation’s president on the ‘magical piece’ of its 10-year health equity plan

Dr. Patrice Matchaba discusses Novartis’ end-to-end approach to tackling systemic health disparities.

By Meagan Parrish • Oct. 17, 2022

BIO’s interim CEO and Alvotech’s new chief quality officer could spell big changes for biotech

What these life science organizations’ latest executive-level appointments mean for the industry.

By Karissa Waddick • Oct. 14, 2022

Coming out of stealth, RIGImmune aims to catch up with ever-mutating viruses

President Susan Sobolov discusses how the startup is building on the work of two powerhouse Yale scientists to advance candidates for viruses — and beyond.

By Kelly Bilodeau • Oct. 13, 2022

Robotic pills could open a world of possibilities for the biologics market

As the oral biologic market heats up, Rani Therapeutics is looking to dominate the field with its robotic pill for treatment of chronic conditions. 

By Karissa Waddick • Oct. 13, 2022

Where the CEO of ADC Therapeutics sees ‘huge potential’ in the tech beyond oncology

The “magic bullet” approach of ADCs has been a breakthrough in cancer care — but this excitement could be just the beginning.

By Meagan Parrish • Oct. 12, 2022

Citius Pharmaceuticals sees golden opportunities in late-stage specialty assets

CEO Leonard Mazur explains how the company’s hoping to unlock the potential of its varied pipeline.

By Karissa Waddick • Oct. 11, 2022

Harnessing the creative energy of California, Alto is advancing a novel approach to psychiatric meds

After making the leap from academia to the world of biotech, CEO Dr. Amit Etkin is hoping to shift the treatment paradigm for neurological conditions.

By Alexandra Pecci • Oct. 11, 2022

The digital therapeutics revolution is happening and Big Pharma is buying in — with caution

Companies like Pfizer, Novartis, Sanofi and BMS are diving into the world of digital therapeutics while recognizing the limitations of the young field.

By Michael Gibney • Oct. 10, 2022

New partnership may give MDMA an edge in the psychedelics space

While LSD and psilocybin steal the spotlight, drug developers are also exploring MDMA for a wide swath of neurological illnesses. 

By Kelly Bilodeau • Oct. 10, 2022

Are you a bad boss?

Pharma execs share their tips for being a better leader.

By Taren Grom • Oct. 7, 2022

Her antibiotic company failed. Now she’s helping others avoid the same fate.

The chief of R&D at CARB-X explains why she believes small antibiotics companies can succeed despite market turmoil.

By Karissa Waddick • Oct. 6, 2022

C-suite shake-ups at 23andMe, Moderna signal new stages of growth

With their latest personnel moves, these life sciences companies are preparing for major business shifts.

By Karissa Waddick • Oct. 5, 2022

It’s electric — speeding up the cell therapy process for scalability

To improve the development of cell therapy-based treatments, many companies are turning to a technology that uses electric fields.

By Alexandra Pecci • Oct. 4, 2022

The 2 areas in life sciences most in need of talent

The industry is feeling the hiring crunch — here’s what pharma companies can do to mitigate the impact.

By Meagan Parrish • Oct. 4, 2022